Previous studies have demonstrated that N-linked glycosylation of PD-L1 increased PD-1 binding, leading to more efficient inhibition of anti-tumor T cell activities; it was also found to interfere with the binding of antibodies used for PD-L1 diagnosis and PD-L1-directed therapy [21,22,23,24,25,26]. This evidence concerns the gene CD274 and neoplasm.